The present invention encompasses compounds of formula (I) wherein the groups R1 to R3, A, B and L and p and q have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
本发明涵盖了式(I)中的化合物,其中基团R1至R3、A、B和L以及p和q具有声明和规范中给定的含义,它们作为突变
EGFR的
抑制剂的用途,含有这类化合物的药物组合物以及它们作为药物/医用品的用途,特别是作为治疗和/或预防肿瘤疾病的药物。